Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Cingulate Inc.

Cingulate® is a biopharmaceutical company utilizing its innovative Precision Timed Release™ (PTR) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products.  
 
We aim to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes.  
 
With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), we believe there are multiple therapeutic areas where our PTR technology may be employed to develop additional product candidates, notably anxiety disorders.

Today we announced the successful manufacturing of CTx-1301 doses for both of our upcoming pivotal Phase 3 trials in pediatric and adolescents with #ADHD, with the fixed-dose study scheduled to begin the week of July 24.
 
Learn more: https://lnkd.in/exPF-XFW
$CING

Our Chairman and CEO, Shane Schaffer, will participate in a company discussion at the Maxim Group's Virtual Healthcare Conference tomorrow. 

To attend, register as an M-Vest member and reserve your seat here: https://lnkd.in/egF5_946
$CING #ADHD

Today we announced the completion of our Phase 3 trial evaluating the onset and duration of CTx-1301 in adults with #ADHD. Results are expected 3Q 2023.
 
Learn more: https://lnkd.in/ev_kre_W
$CING

Catch the live replay from Benzinga All Access this week to hear Shane Schaffer, $CING CEO, and Tim Moore, SVP of Biotech at Indegene, discuss our joint commercialization agreement and how we’ll leverage #AI to launch in the $20B #ADHD market: https://lnkd.in/e9pkPHhW

Our CEO, Shane Schaffer, joined fellow Kansas Citian and Royals broadcaster, Joel Goldberg, for an episode of his “Rounding The Bases” podcast. 

Listen to learn about our work in #ADHD and ambitions to become a powerhouse in the pharmaceutical industry – right from #KansasCity.

Today we announced first quarter 2023 financial results, including clinical and business updates on the Phase 3 program for our lead candidate, CTx-1301, for the treatment of #ADHD.

Read our press release to learn more: https://lnkd.in/eyzmJnkn
$CING

Our CEO, Shane Schaffer, stopped by Nasdaq’s Innovators with Jane King to discuss how we’re tackling unmet needs in #ADHD with our lead candidate CTx-1301 (dexmethylphenidate).

Watch the full video: https://lnkd.in/ej8aanrP
$CING

Today we announced the successful transfer of CTx-1301 proprietary Precision Timed Release™ manufacturing processes to Societal CDMO, keeping us on track to meet previously announced clinical timelines for our Phase 3 program in #ADHD. 

Learn more: https://lnkd.in/d36fuHaW
$CING Societal™ CDMO

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables	1.90M -	975.11K 48.57%	264.69K 72.86%	762.36K 188.02%
accumulated other comprehensive income loss	32 -	165 415.63%	165 0%
cash and cash equivalents	418.47K -	1.20M 186.20%	16.49M 1,277.07%	5.36M 67.52%
cash and short term investments	437.19K -	1.20M 174.16%	16.49M 1,276.07%	5.36M 67.53%
common stock	615.85K -	1.29M 109.84%	1.13K 99.91%	1.13K 0%
deferred revenue	524.03K -	1.22M 131.96%	601.30K 50.53%
deferred revenue non current
deferrred tax liabilities non current			-510.68M -	-325.80M 36.20%	-563.53M 72.97%
goodwill
goodwill and intangible assets
intangible assets
inventory				100.34K -
long term debt	1.71M -	1.11M 35.22%	866.04K 21.98%	510.24K 41.08%
long term investments
net debt	1.67M -	848.99K 49.19%	-15.61M 1,938.84%	170.01K 101.09%
net receivables	113.24K -	151.77K 34.03%	690.25K 354.79%	234.43K 66.04%
other assets
other current assets				2.18M -
other current liabilities	155.49K -	234.17K 50.60%	295.60K 26.23%	1.23M 317.60%
other liabilities
other non current assets	143.02K -		-1.36B -	-5.91B 334.95%
other non current liabilities		23.61K -	510.68M 2,162,406.88%	325.80M 36.20%
othertotal stockholders equity			72.57M -	-1.13K 100.00%
preferred stock
property plant equipment net	4.16M -	4.00M 3.89%	4.00M 0.16%	3.54M 11.70%	-524.83M 14,944.89%
retained earnings			-51.73M -	-69.41M 34.17%
short term debt	375.82K -	936.59K 149.21%	15.10K 98.39%	5.02M 33,127.70%
short term investments	18.72K -	933 95.02%	933 0%
tax assets			1.36B -	5.91B 334.95%	13.19B 123.39%
tax payables
total assets	5.28M -	5.79M 9.60%	22.89M 295.44%	11.41M 50.17%	12.67B 110,988.78%
total current assets	978.32K -	1.79M 82.95%	18.88M 954.95%	7.87M 58.32%
total current liabilities	2.95M -	3.36M 13.90%	1.18M 64.99%	7.01M 495.98%
total debt	2.09M -	2.05M 2.05%	881.13K 56.95%	5.53M 527.18%
total investments	18.72K -	933 95.02%	933 0%
total liabilities	4.66M -	4.50M 3.64%	2.04M 54.56%	7.52M 268.29%	-563.53M 7,590.77%
total liabilities and stockholders equity	5.28M -	5.79M 9.60%	22.89M 295.44%	-61.89M 370.40%	12.67B 20,572.88%
total non current assets	4.30M -	4.00M 7.08%	4.00M 0.16%	3.54M 11.70%	12.67B 358,267.40%
total non current liabilities	1.71M -	1.13M 33.84%	866.04K 23.61%	510.24K 41.08%	-563.53M 110,545.77%
total stockholders equity	615.88K -	1.29M 109.85%	20.84M 1,512.73%	-69.41M 433.00%

COM:CINGULATE

Cingulate Inc.

Last Close

0.37

26/07 20:00

Market Cap

4.76M

Beta: -

Volume Today

292.55K

Avg: -

Preview